GVHD biomarkers measured over time. Neither ST2 (A) nor REG3a (B) significantly changed over time compared with baseline in patients with a day 28 CR or PR to therapy. (C) However, AREG was significantly lower at day 56 compared with baseline in day 28 responders. Data are presented as mean ± SEM. *P < .05 compared with baseline.